[Treatment of non-muscle invasive bladder tumours by instillations of mitomycin C and BCG: a survey on French urologists by the French Urological Association].
OBJECTIVE
To survey the French urologists in order to evaluate their practice of BCG and mitomycin C instillations in the treatment of non muscle invasive bladder tumours (NMIBT).


METHODS
The survey was performed in 2008 on French urologists registered by the French Urological Association (AFU), using online self-administered questionnaires.


RESULTS
One hundred and fifty-six urologists answered the questionnaire. The majority of responders reported indications for bladder instillations that were closed to the AFU recommendations, but for 25% of the respondents, indications were far away from the recommendations. Seventy-nine percent of respondents said that first line plus maintenance BCG therapy was more efficient than first line alone. However, many of the respondents reported that maintenance BCG therapy was not well accepted by patients (46%), was not easy to organize (28%), and was not well tolerated by patients (56%). Eighty-eight percent of respondents said using ofloxacin to prevent BCG adverse effects, but the protocol they were using was not clearly defined. Definition of BCG therapy failure given by respondents was close to the AFU one, but the way to manage it was heterogeneous.


CONCLUSIONS
Responses of the 156 urologists who took part in this survey should help to evaluate French urologists attitude toward bladder instillations in the treatment of NMIBT. Although they were not so far from the AFU recommendations, urologists' practices of instillations appeared to be heterogeneous. Some points requiring clarification were highlighted in this study.
Descazeaud
A
A
Service de Chirurgie Urologique, Hôpital Dupuytren, CHU de Limoges, Limoges, France. aurelien.descazeaud@chu-limoges.fr
Mignard
J-P
JP
Davin
J-L
JL
Irani
J
J
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000283:Administration, Intravesical; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage*; D005602:France; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage*; D009361:Neoplasm Invasiveness; D010818:Practice Patterns, Physicians'; D012955:Societies, Medical; D011795:Surveys and Questionnaires; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014572:Urology
D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D001500:BCG Vaccine; D016685:Mitomycin